{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:56:33Z","timestamp":1790459793921,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["200102\/Z\/15\/Z"],"award-info":[{"award-number":["200102\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["094849\/Z\/10\/Z"],"award-info":[{"award-number":["094849\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41380-019-0502-5","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T05:25:42Z","timestamp":1567229142000},"page":"1310-1320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-2566","authenticated-orcid":false,"given":"Robert A.","family":"McCutcheon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3531-8006","authenticated-orcid":false,"given":"Yuya","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haridha","family":"Pandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-490X","authenticated-orcid":false,"given":"Luke","family":"Vano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Reis","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"502_CR1","first-page":"1","volume":"6736","author":"O Howes","year":"2014","unstructured":"Howes O, Murray R. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;6736:1\u201311.","journal-title":"Lancet"},{"key":"502_CR2","first-page":"1","volume":"6736","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;6736:1\u201312.","journal-title":"Lancet"},{"key":"502_CR3","doi-asserted-by":"crossref","unstructured":"Kaar SJ, Natesan, S., McCutcheon R, Howes OD. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology.\u00a0Neuropharmacol. 2019;107704.","DOI":"10.1016\/j.neuropharm.2019.107704"},{"key":"502_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","volume":"72","author":"O Agid","year":"2011","unstructured":"Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72:1439\u201344.","journal-title":"J Clin Psychiatry"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1017\/S0033291710002035","volume":"41","author":"TR Marques","year":"2011","unstructured":"Marques TR, Arenovich T, Agid O, Sajeev G, Muth\u00e9n B, Chen L, et al. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med. 2011;41:1481\u20138.","journal-title":"Psychol Med"},{"key":"502_CR6","doi-asserted-by":"crossref","unstructured":"Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231\u201340.","DOI":"10.1017\/S0033291716002014"},{"key":"502_CR7","doi-asserted-by":"crossref","unstructured":"Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47:1981\u201389.","DOI":"10.1017\/S0033291717000435"},{"key":"502_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174:216\u201329.","journal-title":"Am J Psychiatry"},{"key":"502_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.bp.113.138578","volume":"205","author":"OD Howes","year":"2014","unstructured":"Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: Type a (hyperdopaminergic) and type b (normodopaminergic). Br J Psychiatry. 2014;205:1\u20133.","journal-title":"Br J Psychiatry"},{"key":"502_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/schbul\/11.3.471","volume":"11","author":"TJ Crow","year":"1985","unstructured":"Crow TJ. The two-syndrome concept: origins and current status. Schizophr Bull. 1985;11:471\u201388.","journal-title":"Schizophr Bull"},{"key":"502_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/d41586-018-07535-2","volume":"563","author":"S Senn","year":"2018","unstructured":"Senn S. Statistical pitfalls of personalized medicine. Nature. 2018;563:619\u201321.","journal-title":"Nature"},{"key":"502_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/2041-210X.12309","volume":"6","author":"S Nakagawa","year":"2015","unstructured":"Nakagawa S, Poulin R, Mengersen K, Reinhold K, Engqvist L, Lagisz M, et al. Meta-analysis of variation: ecological and evolutionary applications and beyond. Methods Ecol Evol. 2015;6:143\u201352.","journal-title":"Methods Ecol Evol"},{"key":"502_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamapsychiatry.2017.2663","volume":"74","author":"SP Brugger","year":"2017","unstructured":"Brugger SP, Howes OD. Heterogeneity and homogeneity of regional brain structure in schizophrenia. JAMA Psychiatry. 2017;74:1104.","journal-title":"JAMA Psychiatry"},{"key":"502_CR14","doi-asserted-by":"publisher","unstructured":"Pillinger T, Osimo EF, Brugger S, Mondelli V, Mccutcheon RA, Howes OD. A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis. 2018;1\u201314. https:\/\/doi.org\/10.1093\/schbul\/sby160.","DOI":"10.1093\/schbul\/sby160"},{"key":"502_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1\u201334.","journal-title":"J Clin Epidemiol"},{"key":"502_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927\u201342.","journal-title":"Am J Psychiatry"},{"key":"502_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261.","journal-title":"Schizophr Bull"},{"key":"502_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE. Gorham DoR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799\u2013812.","journal-title":"Psychol Rep"},{"key":"502_CR19","volume-title":"Scale for the assessment of negative symptoms.","author":"NC Andreasen","year":"1984","unstructured":"Andreasen NC. Scale for the assessment of negative symptoms. Iowa City: University of Iowa; 1984."},{"key":"502_CR20","volume-title":"Scale for the assessment of positive symptoms.","author":"NC Andreasen","year":"1984","unstructured":"Andreasen NC. Scale for the assessment of positive symptoms. Iowa City: University of Iowa; 1984."},{"key":"502_CR21","doi-asserted-by":"publisher","unstructured":"Higgins JP, Green S Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2008. https:\/\/doi.org\/10.1002\/9780470712184.ch5.","DOI":"10.1002\/9780470712184.ch5"},{"key":"502_CR22","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the ddd method: Table 1. Schizophr Bull. 2016;42:S90\u2013S94.","journal-title":"Schizophr Bull"},{"key":"502_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/pcn.12275","volume":"69","author":"T Inada","year":"2015","unstructured":"Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69:440\u20137.","journal-title":"Psychiatry Clin Neurosci"},{"key":"502_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/00018730801893043","volume":"57","author":"Z Eisler","year":"2008","unstructured":"Eisler Z, Bartos I, Kert\u00e9sz J. Fluctuation scaling in complex systems: Taylor\u2019s law and beyond. Adv Phys. 2008;57:89\u2013142.","journal-title":"Adv Phys"},{"key":"502_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1176\/ajp.151.6.825","volume":"151","author":"S Marder","year":"1994","unstructured":"Marder S, Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825\u201335.","journal-title":"Am J Psychiatry"},{"key":"502_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","volume":"13","author":"G Chouinard","year":"1993","unstructured":"Chouinard G, Jones B, Remington G, Bloom D, Addington D, Macewan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25\u201340.","journal-title":"J Clin Psychopharmacol."},{"key":"502_CR27","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4088\/JCP.v58n1205","volume":"58","author":"SR Marder","year":"1997","unstructured":"Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538\u201346.","journal-title":"J Clin Psychiatry"},{"key":"502_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1214\/aos\/1176346577","volume":"13","author":"J Hartigan","year":"1985","unstructured":"Hartigan J, Hartigan P. The dip test of unimodality. Ann Stat. 1985;13:70\u201384.","journal-title":"Ann Stat"},{"key":"502_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"502_CR30","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"502_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/17476348.2018.1403318","volume":"12","author":"SJH Vijverberg","year":"2018","unstructured":"Vijverberg SJH, Farzan N, Slob EMA, Neerincx AH, Maitland-van der Zee AH. Treatment response heterogeneity in asthma: the role of genetic variation. Expert Rev Respir Med. 2018;12:55\u201365.","journal-title":"Expert Rev Respir Med"},{"key":"502_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1463-1326.2010.01248.x","volume":"12","author":"RA Cantrell","year":"2010","unstructured":"Cantrell RA, Alatorre CI, Davis EJ, Zarotsky V, Le Nestour E, Carter GC, et al. A review of treatment response in type 2 diabetes: Assessing the role of patient heterogeneity. Diabetes, Obes Metab. 2010;12:845\u201357.","journal-title":"Diabetes, Obes Metab"},{"key":"502_CR33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/520609a","volume":"520","author":"NJ Schork","year":"2015","unstructured":"Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015;520:609\u201311.","journal-title":"Nature"},{"key":"502_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1192\/bjp.2018.71","volume":"213","author":"KFM Marwick","year":"2018","unstructured":"Marwick KFM, Stevenson AJ, Davies C, Lawrie SM. Application of n-of-1 treatment trials in schizophrenia: Systematic review. Br J Psychiatry. 2018;213:398\u2013403.","journal-title":"Br J Psychiatry"},{"key":"502_CR35","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","volume":"25","author":"CU Correll","year":"2010","unstructured":"Correll CU. From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25:S12\u2013S21.","journal-title":"Eur Psychiatry"},{"key":"502_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881114563634","volume":"29","author":"O Howes","year":"2015","unstructured":"Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21 st century. J Psychopharmacol. 2015;29:97\u2013115.","journal-title":"J Psychopharmacol"},{"key":"502_CR37","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","volume":"71","author":"BR Rutherford","year":"2014","unstructured":"Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials ameta-analysis. JAMA Psychiatry. 2014;71:1409\u201321.","journal-title":"JAMA Psychiatry"},{"key":"502_CR38","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1176\/appi.ajp.2013.12030315","volume":"170","author":"O Agid","year":"2013","unstructured":"Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D, et al. Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970\u20132010. Am J Psychiatry. 2013;170:1335\u201344.","journal-title":"Am J Psychiatry"},{"key":"502_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nrn3976","volume":"16","author":"TD Wager","year":"2015","unstructured":"Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci. 2015;16:403\u201318.","journal-title":"Nat Rev Neurosci"},{"key":"502_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJMp1504023","volume":"373","author":"TJ Kaptchuk","year":"2015","unstructured":"Kaptchuk TJ, Miller FG. Placebo effects in medicine. N Engl J Med. 2015;373:8\u20139.","journal-title":"N Engl J Med"},{"key":"502_CR41","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.psych.59.113006.095941","volume":"59","author":"DD Price","year":"2008","unstructured":"Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565\u201390.","journal-title":"Annu Rev Psychol"},{"key":"502_CR42","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1126\/science.1067176","volume":"295","author":"P Petrovic","year":"2002","unstructured":"Petrovic P. Placebo and opioid analgesia- imaging a shared neuronal network. Science. 2002;295:1737\u201340.","journal-title":"Science"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41380-019-0502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-019-0502-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-019-0502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:37Z","timestamp":1684616437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0502-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1038\/s41380-019-0502-5","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RM, TP, AM, HP and LV declare no financial conflicts of interest. YM has received manuscript fees or speaker\u2019s honoraria from Sumitomo Dainippon Pharma and Yoshitomi Yakuhin, fellowship grants from Japan Society for the Promotion of Science, Astellas Foundation for Research on Metabolic Disorders, Japanese Society of Clinical Neuropsychopharmacology, and Mochida Memorial Foundation for Medical and Pharmaceutical Research, and consultant fees from Bracket within the past three years. ODH has received investigator-initiated research funding from and\/or participated in advisory\/speaker meetings organised by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. Neither ODH or his family have been employed by or have holdings\/a financial stake in any biomedical company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}